GLAXF News and Press, GlaxoSmithKline Plc From 03/07/19

New York-based pharma giant Pfizer (NYSE: PFE) sold US$5bn of new corporate bonds Monday in five parts, as the company contributes to a groundswell of issuance amid low U.S. interest rates. The senior unsecured deal, comprised of maturities ranging from two- to 30-years, attracted decent dem...

Introduction: GlaxoSmithKline Plc ( OTCPK:GLAXF ) is a global healthcare conglomerate that ranks among the top 10 pharmaceutical companies in the world. Headquartered in the UK, it operates through three business segments namely Pharmaceuticals , Vaccines and Consumer Healthcare . GLA...

With two candidates at Phase 1 of development and others at a preclinical stage, Alector (ALEC) is a name that only long time investors will appreciate. The company could take many years to report revenues from commercialization. The stock price may increase in 2019 as Alector reports new resu...

International stocks, whether it be in Europe or emerging markets, have had a rough 2018 so far. There is a sense that there must be some bargains out there, but many investors are not comfortable with those markets, and don't know how they can separate the wheat from the chaff . ...

With Yale University, Pfizer Inc. ( PFE ), Roche Ltd. ( RHHBY ) and Merck ( MRK ) collaborating with Arvinas Holding ( ARVN ) and shares at 2.5 its cash per share, the company seems a name that should retain the attention of investors. Having said that, Arvinas, which conducts research treatme...

Gilead's ( GILD ) vaunted HCV franchise grew quarterly revenue by double digits in Q2 2018. HCV was less than 20% of total revenue, down from over 40% in the year earlier period. Its HIV franchise will likely drive the narrative from here. That could be problematic as GlaxoSmithKline ( GSK ), ...

With remarkable investors like the foundation of Bill Gates, agreements with GlaxoSmithKline Plc ( GLAXF ) and a total addressable market of more than $4 billion, Liquidia Technologies, Inc. (LQDA) seems like a must-follow stock. Furthermore, Liquidia’s product candidate LIQ861 is at Ph...

Actionable Conclusions (1-10): Analysts Projected 6% To 23% Net Gains For Top Ten Healthcare Stocks By June 2019 Just two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year, based on broker 1-year target prices. (They a...

Actionable Conclusions (1-10): Analysts Predicted 9.8% To 41.2% Net Gains For Top Ten Healthcare Equities By April 2019 Two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. ...

Actionable Conclusions (1-10): Analysts Predicted 4.22% To 26.43% Net Gains For Top Ten Healthcare Equities By February 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (...